business
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Key takeaways
- Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1.
- Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while remaining on Immunic's board of directors.
- The company is also preparing for potential regulatory filings, approval efforts, and commercialization activities.
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO Anusuya Lahiri Wed, May 27, 2026 at 5:17 PM GMT+7 2 min read IMUX Immunic, Inc (NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization.
Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1.
Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while remaining on Immunic's board of directors.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop